CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 0.2%

CRISPR Therapeutics AG (NASDAQ:CRSP)’s stock price was down 0.2% during mid-day trading on Monday . The company traded as low as $54.37 and last traded at $54.95. Approximately 262,647 shares were traded during mid-day trading, a decline of 86% from the average daily volume of 1,824,210 shares. The stock had previously closed at $55.05.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Morgan Stanley increased their price target on CRISPR Therapeutics from $46.00 to $48.00 and gave the stock an “underweight” rating in a research report on Monday, February 26th. Wolfe Research began coverage on CRISPR Therapeutics in a research note on Thursday, February 15th. They issued a “peer perform” rating for the company. Needham & Company LLC reissued a “buy” rating and set a $90.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, April 11th. Royal Bank of Canada boosted their price objective on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the stock a “sector perform” rating in a research report on Thursday, February 22nd. Finally, TheStreet raised CRISPR Therapeutics from a “d+” rating to a “c” rating in a research note on Friday, February 23rd. Three analysts have rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $76.29.

CRISPR Therapeutics Price Performance

The business’s 50 day moving average is $72.21 and its 200-day moving average is $63.86.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.95. The company had revenue of $201.20 million during the quarter, compared to analyst estimates of $148.72 million. The company’s revenue for the quarter was up 3253.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.41) earnings per share. On average, equities analysts anticipate that CRISPR Therapeutics AG will post -6.24 EPS for the current fiscal year.

Insider Activity

In related news, General Counsel James R. Kasinger sold 1,913 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total value of $152,408.71. Following the sale, the general counsel now directly owns 57,371 shares in the company, valued at $4,570,747.57. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, General Counsel James R. Kasinger sold 2,801 shares of the stock in a transaction on Monday, March 11th. The shares were sold at an average price of $78.26, for a total transaction of $219,206.26. Following the transaction, the general counsel now directly owns 60,070 shares of the company’s stock, valued at $4,701,078.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, General Counsel James R. Kasinger sold 1,913 shares of CRISPR Therapeutics stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total transaction of $152,408.71. Following the completion of the sale, the general counsel now directly owns 57,371 shares of the company’s stock, valued at $4,570,747.57. The disclosure for this sale can be found here. Insiders sold 133,992 shares of company stock valued at $9,157,835 over the last quarter. 4.10% of the stock is owned by company insiders.

Institutional Trading of CRISPR Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Blue Trust Inc. acquired a new position in CRISPR Therapeutics during the fourth quarter worth $32,000. Bourgeon Capital Management LLC boosted its stake in CRISPR Therapeutics by 1,000.0% during the 4th quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock valued at $34,000 after purchasing an additional 500 shares during the last quarter. CWM LLC increased its holdings in CRISPR Therapeutics by 80.7% during the 3rd quarter. CWM LLC now owns 582 shares of the company’s stock worth $26,000 after purchasing an additional 260 shares in the last quarter. NBC Securities Inc. raised its position in CRISPR Therapeutics by 257.6% in the 1st quarter. NBC Securities Inc. now owns 608 shares of the company’s stock valued at $41,000 after buying an additional 438 shares during the last quarter. Finally, Principal Securities Inc. bought a new stake in CRISPR Therapeutics during the fourth quarter worth $41,000. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.